132 related articles for article (PubMed ID: 8572659)
1. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease.
Furtado S; Suchowersky O; Rewcastle B; Graham L; Klimek ML; Garber A
Ann Neurol; 1996 Jan; 39(1):132-6. PubMed ID: 8572659
[TBL] [Abstract][Full Text] [Related]
2. CAG repeat number governs the development rate of pathology in Huntington's disease.
Penney JB; Vonsattel JP; MacDonald ME; Gusella JF; Myers RH
Ann Neurol; 1997 May; 41(5):689-92. PubMed ID: 9153534
[TBL] [Abstract][Full Text] [Related]
3. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
[TBL] [Abstract][Full Text] [Related]
4. Predictors of neuropathological severity in 100 patients with Huntington's disease.
Rosenblatt A; Abbott MH; Gourley LM; Troncoso JC; Margolis RL; Brandt J; Ross CA
Ann Neurol; 2003 Oct; 54(4):488-93. PubMed ID: 14520661
[TBL] [Abstract][Full Text] [Related]
5. Trinucleotide repeat length and rate of progression of Huntington's disease.
Illarioshkin SN; Igarashi S; Onodera O; Markova ED; Nikolskaya NN; Tanaka H; Chabrashwili TZ; Insarova NG; Endo K; Ivanova-Smolenskaya IA
Ann Neurol; 1994 Oct; 36(4):630-5. PubMed ID: 7944295
[TBL] [Abstract][Full Text] [Related]
6. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.
Andrew SE; Goldberg YP; Kremer B; Telenius H; Theilmann J; Adam S; Starr E; Squitieri F; Lin B; Kalchman MA
Nat Genet; 1993 Aug; 4(4):398-403. PubMed ID: 8401589
[TBL] [Abstract][Full Text] [Related]
7. MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters.
Vymazal J; Klempír J; Jech R; Zidovská J; Syka M; Růzicka E; Roth J
J Neurol Sci; 2007 Dec; 263(1-2):20-5. PubMed ID: 17585943
[TBL] [Abstract][Full Text] [Related]
8. Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number.
Gómez-Ansón B; Alegret M; Muñoz E; Monté GC; Alayrach E; Sánchez A; Boada M; Tolosa E
Parkinsonism Relat Disord; 2009 Mar; 15(3):213-9. PubMed ID: 18632301
[TBL] [Abstract][Full Text] [Related]
9. Brain structure in preclinical Huntington's disease.
Paulsen JS; Magnotta VA; Mikos AE; Paulson HL; Penziner E; Andreasen NC; Nopoulos PC
Biol Psychiatry; 2006 Jan; 59(1):57-63. PubMed ID: 16112655
[TBL] [Abstract][Full Text] [Related]
10. Trinucleotide repeat length instability and age of onset in Huntington's disease.
Duyao M; Ambrose C; Myers R; Novelletto A; Persichetti F; Frontali M; Folstein S; Ross C; Franz M; Abbott M
Nat Genet; 1993 Aug; 4(4):387-92. PubMed ID: 8401587
[TBL] [Abstract][Full Text] [Related]
11. [Huntington's chorea: clinical aspects, genetics and current diagnosis].
Spiegel R
Ther Umsch; 1995 Dec; 52(12):814-20. PubMed ID: 8539653
[TBL] [Abstract][Full Text] [Related]
12. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.
Snell RG; MacMillan JC; Cheadle JP; Fenton I; Lazarou LP; Davies P; MacDonald ME; Gusella JF; Harper PS; Shaw DJ
Nat Genet; 1993 Aug; 4(4):393-7. PubMed ID: 8401588
[TBL] [Abstract][Full Text] [Related]
13. Regional and cellular gene expression changes in human Huntington's disease brain.
Hodges A; Strand AD; Aragaki AK; Kuhn A; Sengstag T; Hughes G; Elliston LA; Hartog C; Goldstein DR; Thu D; Hollingsworth ZR; Collin F; Synek B; Holmans PA; Young AB; Wexler NS; Delorenzi M; Kooperberg C; Augood SJ; Faull RL; Olson JM; Jones L; Luthi-Carter R
Hum Mol Genet; 2006 Mar; 15(6):965-77. PubMed ID: 16467349
[TBL] [Abstract][Full Text] [Related]
14. The relationship between CAG repeat length and clinical progression in Huntington's disease.
Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
[TBL] [Abstract][Full Text] [Related]
15. Advances in Huntington's disease diagnostics: development of a standard reference material.
Levin BC; Richie KL; Jakupciak JP
Expert Rev Mol Diagn; 2006 Jul; 6(4):587-96. PubMed ID: 16824032
[TBL] [Abstract][Full Text] [Related]
16. Variation of selective gray and white matter atrophy in Huntington's disease.
Jech R; Klempír J; Vymazal J; Zidovská J; Klempírová O; Růzicka E; Roth J
Mov Disord; 2007 Sep; 22(12):1783-9. PubMed ID: 17579363
[TBL] [Abstract][Full Text] [Related]
17. Caudate nucleus atrophy in Huntington's disease and its relationship with clinical and genetic parameters.
Roth J; Klempìi J; Jech R; Zidovská J; Uhrová T; Doubek P; Ulmanová O; Brozová H; Volfová M; Serranová T; Ruzicka E
Funct Neurol; 2005; 20(3):127-30. PubMed ID: 16324236
[TBL] [Abstract][Full Text] [Related]
18. Computer simulation of expansions of DNA triplet repeats in the fragile X syndrome and Huntington's disease.
Bat O; Kimmel M; Axelrod DE
J Theor Biol; 1997 Sep; 188(1):53-67. PubMed ID: 9299309
[TBL] [Abstract][Full Text] [Related]
19. Regional specificity of brain atrophy in Huntington's disease.
Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E
Exp Neurol; 1998 Dec; 154(2):663-72. PubMed ID: 9878201
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of the Huntington's disease gene in New Zealand.
Whitefield JE; Williams L; Snow K; Dixon J; Winship I; Stapleton PM; Faull RM; Love DR
N Z Med J; 1996 Feb; 109(1015):27-30. PubMed ID: 8606810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
